Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Teva Pharmaceutical has surged 110% in the last year, hitting a 52-week high of $40.79 per share, driven by its pivot from generic to branded drugs. The company's innovative portfolio of three branded products is projected to generate $3.7 billion in 2026 revenue, while net debt has decreased from $18.4 billion (end of 2022) to $12.9 billion, earning a credit rating upgrade to investment-grade status. With peak annual sales of $10 billion anticipated from its late-stage pipeline and earnings expected to grow 40.7% between 2026-2027, analysts view the stock as undervalued at 12.9x forward earnings.